Cocrystal Pharma (COCP) Net Income towards Common Stockholders (2010 - 2026)

Cocrystal Pharma (COCP) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1.3% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$9.9 million (up 45.1% YoY), and the FY2025 full-year result was -$9.7 million, up 48.07% from the prior year.
• Net Income towards Common Stockholders rose to -$2.3 million in Q1 2026, from -$2.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.3 million in Q1 2025 to a low of -$24.5 million in Q2 2022.
• A 5-year average of -$5.3 million and a median of -$4.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 529.45% in 2022 and jumped 81.51% in 2023, its largest moves.
• Tracing COCP's Net Income towards Common Stockholders over 5 years: stood at -$4.4 million in 2022, then decreased by 19.29% to -$5.2 million in 2023, then soared by 48.99% to -$2.6 million in 2024, then fell by 7.03% to -$2.8 million in 2025, then rose by 17.61% to -$2.3 million in 2026.
• Business Quant data shows COCP's Net Income towards Common Stockholders at -$2.3 million in Q1 2026, -$2.8 million in Q4 2025, and -$2.3 million in Q3 2025.